Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384966 · ClinicalTrials.gov registry record · Phase 2
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
A Phase 2 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 2
- Development phase
- 346
- Enrollment target
NCT03384966: Completed Phase 2 study, sponsored by Viatris Innovation.
NCT03384966 is a Phase 2 study that has completed, run by Viatris Innovation. The registered enrollment target is 346 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03384966, a Phase 2 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 346 participants
- Enrollment target
Study Summary
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. This study will also help to find out more about the safety of this new drug.
Primary Outcome
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting from 30 minutes after the administration of study treatment and lasting for at least 3 hours was considered a "respond
Interventions
- DRUG Placebo
- DRUG Selatogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-09-18 |
| Phase | Phase 2 |
What the finished NCT03384966 record still lists
NCT03384966 is an interventional study that assigns participants to a tested intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03384966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03384966 about?
NCT03384966 is a clinical study titled "A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease". The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a ...
What is the current status of trial NCT03384966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2018-01-24. Estimated completion is 2018-09-18.
What interventions are being tested in trial NCT03384966?
The interventions under investigation include: Placebo (DRUG), Selatogrel (DRUG).
Who is sponsoring clinical trial NCT03384966?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03384966's enrollment target sits among peer trials
346 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI